Elise A. Olsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Elise A. Olsen has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
Madeleine Duvic
6 shared publicationsDavid Whiting
3 shared publicationsGary Wood
3 shared publicationsLauren Pinter-Brown
3 shared publicationsMarie-France Demierre
3 shared publicationsMark Pittelkow
3 shared publications
Latest Publications
- 1 September 2012
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 67 (3) , 379-386
Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo
- 1 September 2012
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 67 (3) , 379-386
Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo
- 1 May 2012
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 148 (5) , 572-574
Subcutaneous Interferon Alfa for the Treatment of Cutaneous Pseudolymphoma
Case Report from JAMA Dermatology — Subcutaneous Interferon Alfa for the Treatment of Cutaneous Pseudolymphoma
- 1 May 2012
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 148 (5) , 572-574
Subcutaneous Interferon Alfa for the Treatment of Cutaneous Pseudolymphoma
Case Report from JAMA Dermatology — Subcutaneous Interferon Alfa for the Treatment of Cutaneous Pseudolymphoma
- 1 July 2011
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 24 (4) , 432-442
Treatment of chemotherapy-induced alopecia
Chemotherapy-induced alopecia has been well documented as a cause of distress to patients undergoing cancer treatment. Despite the importance of hair loss to patients, however, patients often receive little more counseling than the advice to purchase a wig or other head covering for the duration of their treatment. Research into non-camouflage (wigs, turbans, and head scarves) treatment methods has been complicated both by a lack of a standardized methodology for evaluating hair loss and hair regrowth and by a lack of human trials. Nevertheless, scalp cooling as a method of preventing hair loss during chemotherapy and 2% topical minoxidil as a therapy for accelerating regrowth after chemotherapy are both effective non-camouflage options for treatment. Other proposed treatments for prevention of hair loss during chemotherapy have demonstrated promise in early trials, but these findings will need validation from rigorous further studies. The increasing number of reports of permanent alopecia not just with pre-bone marrow transplant, high-dose busulfan, and cyclophosphamide regimens but also with standard breast cancer chemotherapy regimens illustrates the importance of further research into treatment methods for chemotherapy-induced alopecia.
- 1 July 2011
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 24 (4) , 432-442
Treatment of chemotherapy-induced alopecia
Chemotherapy-induced alopecia has been well documented as a cause of distress to patients undergoing cancer treatment. Despite the importance of hair loss to patients, however, patients often receive little more counseling than the advice to purchase a wig or other head covering for the duration of their treatment. Research into non-camouflage (wigs, turbans, and head scarves) treatment methods has been complicated both by a lack of a standardized methodology for evaluating hair loss and hair regrowth and by a lack of human trials. Nevertheless, scalp cooling as a method of preventing hair loss during chemotherapy and 2% topical minoxidil as a therapy for accelerating regrowth after chemotherapy are both effective non-camouflage options for treatment. Other proposed treatments for prevention of hair loss during chemotherapy have demonstrated promise in early trials, but these findings will need validation from rigorous further studies. The increasing number of reports of permanent alopecia not just with pre-bone marrow transplant, high-dose busulfan, and cyclophosphamide regimens but also with standard breast cancer chemotherapy regimens illustrates the importance of further research into treatment methods for chemotherapy-induced alopecia.
- Top Cited Papers
- 20 June 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (18) , 2598-2607
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
Mycosis fungoides (MF) and Sézary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that distinguish them from other types of non-Hodgkin's lymphomas. Clinical trials in MF/SS have suffered from a lack of standardization in evaluation, staging, assessment, end points, and response criteria. Recently defined criteria for the diagnosis of early MF, guidelines for initial evaluation, and revised staging and classification criteria for MF and SS now offer the potential for uniform staging of patients enrolled in clinical trials for MF/SS. This article presents consensus recommendations for the general conduct of clinical trials of patients with MF/SS as well as methods for standardized assessment of potential disease manifestations in skin, lymph nodes, blood, and visceral organs, and definition of end points and response criteria. These guidelines should facilitate collaboration among investigators and collation of data from sponsor-generated or investigator-initiated clinical trials involving patients with MF or SS.
- 20 June 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (18) , 2598-2607
Top Cited PapersClinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
Mycosis fungoides (MF) and Sézary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that distinguish them from other types of non-Hodgkin's lymphomas. Clinical trials in MF/SS have suffered from a lack of standardization in evaluation, staging, assessment, end points, and response criteria. Recently defined criteria for the diagnosis of early MF, guidelines for initial evaluation, and revised staging and classification criteria for MF and SS now offer the potential for uniform staging of patients enrolled in clinical trials for MF/SS. This article presents consensus recommendations for the general conduct of clinical trials of patients with MF/SS as well as methods for standardized assessment of potential disease manifestations in skin, lymph nodes, blood, and visceral organs, and definition of end points and response criteria. These guidelines should facilitate collaboration among investigators and collation of data from sponsor-generated or investigator-initiated clinical trials involving patients with MF or SS.
- 14 June 2011
- Published by Wiley in American Journal of Hematology
- Vol. 86 (7) , 627-630
Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma
- 14 June 2011
- Published by Wiley in American Journal of Hematology
- Vol. 86 (7) , 627-630
Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma
- 1 May 2011
- Published by Elsevier in Journal of Supportive Oncology
- Vol. 9 (3) , e13-e19
An In-Depth Assessment of the Impact of Pruritus on Health-Related Quality of Life of Patients with Mycosis Fungoides/Sézary Syndrome
- 1 May 2011
- Published by Elsevier in Journal of Supportive Oncology
- Vol. 9 (3) , e13-e19
An In-Depth Assessment of the Impact of Pruritus on Health-Related Quality of Life of Patients with Mycosis Fungoides/Sézary Syndrome
- 1 May 2011
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 24 (3) , 311-319
Investigative guidelines for alopecia areata
The reported efficacy of various treatments for alopecia is difficult to compare based on a general lack of consideration in case reports/series and clinical trials of the spontaneous regrowth or baseline prognostic factors seen in alopecia areata and a general lack of quantification of hair growth. This report will give both the investigator and clinician guidelines for clinical trial design that will take into account variables known to effect efficacy results such as baseline severity, pattern, and duration of hair loss, age of the subject, and concomitant conditions that may impact on potential regrowth. Reliable methods of assessment of efficacy and response criteria that will enable direct comparison of results between agents will also be discussed.
- 1 May 2011
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 24 (3) , 311-319
Investigative guidelines for alopecia areata
The reported efficacy of various treatments for alopecia is difficult to compare based on a general lack of consideration in case reports/series and clinical trials of the spontaneous regrowth or baseline prognostic factors seen in alopecia areata and a general lack of quantification of hair growth. This report will give both the investigator and clinician guidelines for clinical trial design that will take into account variables known to effect efficacy results such as baseline severity, pattern, and duration of hair loss, age of the subject, and concomitant conditions that may impact on potential regrowth. Reliable methods of assessment of efficacy and response criteria that will enable direct comparison of results between agents will also be discussed.
- 1 February 2011
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 64 (2) , 245-252
Central hair loss in African American women: Incidence and potential risk factors
- 1 February 2011
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 64 (2) , 245-252
Central hair loss in African American women: Incidence and potential risk factors
- 3 September 2010
- Published by Springer Nature
- p. 381-386
Chemotherapy-Induced Alopecia: Overview and Methodology for Characterizing Hair Changes and Regrowth
- 3 September 2010
- Published by Springer Nature
- p. 381-386
Chemotherapy-Induced Alopecia: Overview and Methodology for Characterizing Hair Changes and Regrowth